Pineoblastomas (PBs) are rare, aggressive pediatric brain tumors of the pineal gland with modest overall survival despite intensive therapy. We sought to define the clinical and molecular spectra of PB to inform new treatment approaches for this orphan cancer. Tumor, blood, and clinical data from 91 patients with PB or supratentorial primitive neuroectodermal tumor (sPNETs/CNS-PNETs), and 2 pineal parenchymal tumors of intermediate differentiation (PPTIDs) were collected from 29 centres in the Rare Brain Tumor Consortium. We used global DNA methylation profiling to define a core group of PB from 72/93 cases, which were delineated into five molecular sub-groups. Copy number, whole exome and targeted sequencing, and miRNA expression analyses were used to evaluate the clinico-pathologic significance of each sub-group. Tumors designated as group 1 and 2 almost exclusively exhibited deleterious homozygous loss-of-function alterations in miRNA biogenesis genes (DICER1, DROSHA, and DGCR8) in 62 and 100% of group 1 and 2 tumors, respectively. Recurrent alterations of the oncogenic MYC-miR-17/92-RB1 pathway were observed in the RB and MYC sub-group, respectively, characterized by RB1 loss with gain of miR-17/92, and recurrent gain or amplification of MYC. PB sub-groups exhibited distinct clinical features: group 1-3 arose in older children (median ages 5.2-14.0 years) and had intermediate to excellent survival (5-year OS of 68.0-100%), while Group RB and MYC PB patients were much younger (median age 1.3-1.4 years) with dismal survival (5-year OS 37.5% and 28.6%, respectively). We identified age < 3 years at diagnosis, metastatic disease, omission of upfront radiation, and chr 16q loss as significant negative prognostic factors across all PBs. Our findings demonstrate that PB exhibits substantial molecular heterogeneity with sub-group-associated clinical phenotypes and survival. In addition to revealing novel biology and therapeutics, molecular sub-grouping of PB can be exploited to reduce treatment intensity for patients with favorable biology tumors.
Keywords: MYC; PNET; PPTID; Pineoblastoma; RB; miRNA.
Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations.Acta Neuropathol. 2020 Feb;139(2):243-257. doi: 10.1007/s00401-019-02101-0. Epub 2019 Nov 25. Acta Neuropathol. 2020. PMID: 31768671
Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials.Acta Neuropathol. 2020 Feb;139(2):259-271. doi: 10.1007/s00401-019-02106-9. Epub 2019 Dec 4. Acta Neuropathol. 2020. PMID: 31802236
Genome-wide molecular characterization of central nervous system primitive neuroectodermal tumor and pineoblastoma.Neuro Oncol. 2011 Aug;13(8):866-79. doi: 10.1093/neuonc/nor070. Neuro Oncol. 2011. PMID: 21798848 Free PMC article.
Pineal and nonpineal supratentorial primitive neuroectodermal tumors.Childs Nerv Syst. 1999 Oct;15(10):586-91. doi: 10.1007/s003810050547. Childs Nerv Syst. 1999. PMID: 10550590 Review.
Patterns of care and survival outcomes in patients with pineal parenchymal tumor of intermediate differentiation: An individual patient data analysis.Radiother Oncol. 2016 Nov;121(2):204-208. doi: 10.1016/j.radonc.2016.10.025. Epub 2016 Nov 16. Radiother Oncol. 2016. PMID: 27865543 Review.